Revolution Medicines (RVMDW) Change in Accured Expenses (2019 - 2026)

Revolution Medicines' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$16.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 1180.63% year-over-year to -$16.7 million; the TTM figure through Mar 2026 stood at $94.0 million (up 109.81% YoY), while the FY2025 annual figure was $112.3 million, up 410.65% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$16.7 million, down from $54.6 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $54.6 million in Q4 2025, with the low at -$21.3 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $7.6 million (2023), against an average of $7.9 million.
• The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses soared 685.1% in 2023, then tumbled 1180.63% in 2026.
• Revolution Medicines' Change in Accured Expenses stood at -$3.0 million in 2022, then sank by 112.1% to -$6.3 million in 2023, then surged by 390.86% to $18.3 million in 2024, then surged by 198.42% to $54.6 million in 2025, then sank by 130.66% to -$16.7 million in 2026.
• Business Quant data shows RVMDW's Change in Accured Expenses at -$16.7 million in Q1 2026, $54.6 million in Q4 2025, and $45.3 million in Q3 2025.